Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/2/2025 | $276.00 | Buy | Redburn Atlantic |
3/4/2025 | $250.00 → $300.00 | Neutral → Buy | Citigroup |
1/7/2025 | $260.00 → $265.00 | In-line → Outperform | Evercore ISI |
12/10/2024 | $265.00 → $275.00 | Buy | Jefferies |
10/30/2024 | Hold → Buy | HSBC Securities | |
10/1/2024 | $235.00 | Neutral | Piper Sandler |
3/25/2024 | $250.00 | Hold → Buy | Argus |
2/26/2024 | $260.00 | Outperform | Leerink Partners |
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test further expands Labcorp's leading blood-based biomarker portfolio for Alzheimer's disease and dementia. The pTau-217/Be
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C., April 1, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer. Labcorp will also offer a vaginal swab self-collect option for sexually transmitted infection (STI) testing. Both solutions are available by physician ord
BURLINGTON, N.C., March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024. Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
BURLINGTON, N.C., March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan
Company Provides 2025 Guidance Results from Continuing Operations versus last year:Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billionDiluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 millionAnnounced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024Full-Year 2025 Guidance:Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4%Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8%Free Ca
BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2025, to stockholders of record as of the close of business on February 27, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and co
Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00
Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously
Evercore ISI upgraded Labcorp Holdings Inc. from In-line to Outperform and set a new price target of $265.00 from $260.00 previously
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
10-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)